NCT00118924View on ClinicalTrials.gov

Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Tick-Borne Encephalitis
Interventions
BIOLOGICAL

LGT(TP21)/DEN4

Live attenuated LGT(TP21)/DEN4 vaccine (one of two doses)

BIOLOGICAL

Placebo

Placebo for LGT(TP21)/DEN4 vaccine

Trial Locations (1)

37232-2581

Vanderbilt University School of Medicine, Nashville

All Listed Sponsors
collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00118924 - Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults | Biotech Hunter | Biotech Hunter